Agios Announces Data From Investigator-led Studies Of Mitapivat In Adults With Sickle Cell Disease Demonstrating Improvements In Anemia, Hemolysis And Sickling Parameters At 63rd ASH Annual Meeting And Exposition

– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients –
 

– Safety Profile Consistent with Previously Reported Clinical Data –

– Agios

– Data Underscore Potential of Mitapivat to Provide Clinically Meaningful Outcomes for Patients –
 

– Safety Profile Consistent with Previously Reported Clinical Data –

– Agios Announces Initiation of Phase 2/3 RISE UP Study of Mitapivat in Adults with Sickle Cell Disease –

– Agios to Host Investor Webcast on Dec. 14, 2021, at 7:30 a.m. ET –